DK2178916T3 - Humane antistoffer mod human cd20 og fremgangsmåde til anvendelse deraf - Google Patents
Humane antistoffer mod human cd20 og fremgangsmåde til anvendelse deraf Download PDFInfo
- Publication number
- DK2178916T3 DK2178916T3 DK08796917.6T DK08796917T DK2178916T3 DK 2178916 T3 DK2178916 T3 DK 2178916T3 DK 08796917 T DK08796917 T DK 08796917T DK 2178916 T3 DK2178916 T3 DK 2178916T3
- Authority
- DK
- Denmark
- Prior art keywords
- ser
- gly
- thr
- leu
- ala
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/867—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody produced via recombinant dna technology
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Biotechnology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
Claims (12)
1. Humant antistof eller antigen-bindende fragment af et antistof, som specifikt binder human CD20 og er i stand til at inducere komplementafhængig cytotoksicitet (CDC) i en human non-Hodgkins B-celle-lymfom-cellelinje med en antistofkoncentration 1 nM eller mindre, har en EC50 på 0,2 nM eller mindre som målt i Daudi-celler eller en EC5o på 0,4 nM eller mindre som målt ved RL-celler og øger symptomfri overlevelsestid nidobbelt eller mere ved intravenøs indgivelse ved en dosis på 10 mg/kg til mus podet med den humane non-Hodgkins B-celle-lymfom-cellelinje Raji i forhold til SCID-mus podet med den humane non-Hodgkins B-celle-lymfom-cellelinje Raji, som modtager 10 mg/kg af en human Fc-kontrol, hvor antistoffet eller antistoffragmentet omfatter: - en komplementært bestemmende region 1 med en tung kæde (HCDR1) og en let kæde CDR1 (LCDR1), hvor HCDR1 og LCDR1 er SEQ ID NO:341 og 349; - en komplementært bestemmende region 2 med en tung kæde (HCDR2) og en let kæde CDR2 (LCDR2), hvor HCDR2 og LCDR2 er SEQ ID NO:343 og 351;og - en komplementært bestemmende region 3 med en tung kæde (HCDR3) og en let kæde CDR3 (LCDR3), hvor HCDR3 og LCDR3 er SEQ ID NO:345 og 353.
2. Humant antistof eller antigen-bindende fragment af et antistof, som specifikt binder human CD20 og er i stand til at inducere komplementafhængig cytotoksicitet (CDC) med en antistofkoncentration på 5 nM eller mindre i en human non-Hodgkins B-celle-lymfom-cellelinje, hvor antistoffet eller fragmentet deraf omfatter en sekvens af en variabel region med tung kæde (HCVR) og en sekvens af variabel region med let kæde (LCVR), hvor HCVR- og LCVR-sekvensen er SEQ ID NO:339 og 347.
3. Humant antistof eller antigen-bindende fragment ifølge krav 2, hvor den nødvendige antistofkoncentrationen til induktion af CDC er 1 nM eller mindre.
4. Humant antistof eller antigen-bindende fragment ifølge krav 3, yderligere kendetegnet ved at have en EC50 på 0,2 nM eller mindre som målt i Daudi- celler eller en EC50 på 0,4 nM eller mindre som målt ved RL-celler.
5. Humant antistof eller antigen-bindende fragment ifølge et af kravene 1 til 4, kendetegnet ved at have en KD eller EC5o på mindst 10'11 M ved måling ved binding til et antigen vist på en celleoverflade.
6. Nukleinsyremolekyle, der koder for det humane antistof eller antistoffragmentet ifølge krav 5.
7. Ekspressionsvektor omfattende nukleinsyremolekylet ifølge krav 6.
8. Fremgangsmåde til fremstilling af et anti-humant CD20-antistof eller antigen-bindende fragment af et antistof, hvilken fremgangsmåde omfatter trinnene med at indføre ekspressionsvektoren ifølge krav 7 i en isoleret værtscelle, dyrkning af cellen under forhold, der gør det muligt at fremstille antistoffet eller antistoffragmentet, og indvinding af antistoffet eller antistoffragmentet, der således er fremstillet.
9. Fremgangsmåde ifølge krav 8, hvorved værtscellen er en E. coli-celle, CHO-celle eller en COS-celle.
10. Farmaceutisk sammensætning omfattende et antistof eller antigenbindende fragment deraf ifølge et af kravene 1 til 5.
11. Antistof eller antigen-bindende fragment af et antistof ifølge et af kravene 1 til 5 til anvendelse med henblik på at svække eller hæmme en CD20-medieret sygdom eller tilstand i et menneske, hvor sygdommen eller tilstanden er udvalgt fra gruppen bestående af non-Hodgkins lymfom, reumatoid artritis, systemisk lupus erythematosus, Crohns sygdom, kronisk lymfatisk leukæmi og en inflammatorisk sygdom.
12. Anvendelse af et antistof eller antigen-bindende fragment af et antistof ifølge et af kravene 1 til 5 ved fremstilling af et medikament til anvendelse med henblik på at svække eller hæmme en CD20-medieret sygdom eller tilstand i et menneske, hvor sygdommen eller tilstanden er udvalgt fra gruppen bestående af non-Hodgkins lymfom, reumatoid artritis, systemisk lupus eryt- hematosus, Crohns sygdom, kronisk lymfom leukæmi og inflammatoriske sygdomme.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US96281107P | 2007-07-31 | 2007-07-31 | |
US6799408P | 2008-03-03 | 2008-03-03 | |
PCT/US2008/071709 WO2009018411A1 (en) | 2007-07-31 | 2008-07-31 | Human antibodies to human cd20 and method of using thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2178916T3 true DK2178916T3 (da) | 2015-01-12 |
Family
ID=40010730
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK08796917.6T DK2178916T3 (da) | 2007-07-31 | 2008-07-31 | Humane antistoffer mod human cd20 og fremgangsmåde til anvendelse deraf |
Country Status (29)
Country | Link |
---|---|
US (3) | US7879984B2 (da) |
EP (1) | EP2178916B1 (da) |
JP (1) | JP5588865B2 (da) |
KR (1) | KR101561020B1 (da) |
CN (1) | CN101809037B (da) |
AU (1) | AU2008282152B2 (da) |
BR (1) | BRPI0813985B1 (da) |
CA (1) | CA2695199C (da) |
CO (1) | CO6260105A2 (da) |
CR (1) | CR11243A (da) |
DK (1) | DK2178916T3 (da) |
DO (1) | DOP2010000037A (da) |
EC (1) | ECSP10010005A (da) |
ES (1) | ES2527297T3 (da) |
GT (1) | GT201000026A (da) |
HK (1) | HK1141811A1 (da) |
HN (1) | HN2010000202A (da) |
MA (1) | MA31634B1 (da) |
ME (1) | ME00973B (da) |
MX (1) | MX2010000970A (da) |
MY (1) | MY147651A (da) |
NI (1) | NI201000016A (da) |
NZ (1) | NZ583019A (da) |
PL (1) | PL2178916T3 (da) |
RU (1) | RU2486205C2 (da) |
SV (1) | SV2010003468A (da) |
TN (2) | TN2010000054A1 (da) |
WO (1) | WO2009018411A1 (da) |
ZA (1) | ZA201000545B (da) |
Families Citing this family (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US20050144655A1 (en) | 2000-10-31 | 2005-06-30 | Economides Aris N. | Methods of modifying eukaryotic cells |
US20090137416A1 (en) | 2001-01-16 | 2009-05-28 | Regeneron Pharmaceuticals, Inc. | Isolating Cells Expressing Secreted Proteins |
US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
AU2004242614B2 (en) | 2003-05-30 | 2011-09-22 | Merus N.V. | Fab library for the preparation of anti vegf and anti rabies virus fabs |
WO2010132532A1 (en) * | 2009-05-15 | 2010-11-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | B cell surface reactive antibodies |
US20120204278A1 (en) | 2009-07-08 | 2012-08-09 | Kymab Limited | Animal models and therapeutic molecules |
US9445581B2 (en) | 2012-03-28 | 2016-09-20 | Kymab Limited | Animal models and therapeutic molecules |
DK3622813T3 (da) | 2009-07-08 | 2021-05-03 | Kymab Ltd | Dyremodeller og terapeutiske molekyler |
RU2549695C2 (ru) | 2009-12-21 | 2015-04-27 | Ридженерон Фармасьютикалз, Инк. | ГУМАНИЗИРОВАННЫЕ FCγR МЫШИ |
ES2612935T3 (es) | 2011-09-19 | 2017-05-19 | Kymab Limited | Anticuerpos, dominios variables y cadenas adaptados para su uso en seres humanos |
EP2761008A1 (en) | 2011-09-26 | 2014-08-06 | Kymab Limited | Chimaeric surrogate light chains (slc) comprising human vpreb |
US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
PL2812443T3 (pl) * | 2012-02-06 | 2020-01-31 | Inhibrx, Inc. | Przeciwciała CD47 i sposoby ich zastosowania |
US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
TW202206465A (zh) * | 2012-11-14 | 2022-02-16 | 美商再生元醫藥公司 | 重組細胞表面捕捉蛋白質 |
US20140140991A1 (en) * | 2012-11-20 | 2014-05-22 | Celgene Avilomics Research, Inc. | Methods of treating a disease or disorder associated with bruton's tyrosine kinase |
WO2014124230A2 (en) | 2013-02-08 | 2014-08-14 | Celgene Avilomics Research, Inc. | Erk inhibitors and uses thereof |
AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
CA2909625C (en) | 2013-04-17 | 2021-06-01 | Signal Pharmaceuticals, Llc | Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer |
US20140314752A1 (en) | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Methods for treating cancer using tor kinase inhibitor combination therapy |
TW201521725A (zh) | 2013-04-17 | 2015-06-16 | Signal Pharm Llc | 使用tor激酶抑制劑組合療法以治療癌症之方法 |
US9783618B2 (en) | 2013-05-01 | 2017-10-10 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
WO2014179661A1 (en) | 2013-05-03 | 2014-11-06 | Celgene Corporation | Methods for treating cancer using combination therapy |
US9492471B2 (en) | 2013-08-27 | 2016-11-15 | Celgene Avilomics Research, Inc. | Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase |
CA2925723A1 (en) | 2013-10-01 | 2015-04-09 | Kymab Limited | Animal models and therapeutic molecules |
MX2016005801A (es) * | 2013-11-07 | 2016-11-29 | Ono Pharmaceutical Co | Terapia de combinacion de un anticuerpo anti cd20 con un inhibidor de btk. |
TWI701042B (zh) | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
EP3179858B1 (en) | 2014-08-13 | 2019-05-15 | Celgene Car Llc | Forms and compositions of an erk inhibitor |
GB201419084D0 (en) | 2014-10-27 | 2014-12-10 | Agency Science Tech & Res | Anti-PD-1 antibodies |
DK3221359T3 (da) | 2014-11-17 | 2020-06-22 | Regeneron Pharma | Fremgangsmåder til tumorbehandling ved anvendelse af CD3XCD20-bispecifikt antistof |
EP3660035A1 (en) | 2015-05-30 | 2020-06-03 | Molecular Templates, Inc. | De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same |
BR112017024610A2 (pt) | 2015-06-24 | 2018-07-31 | F. Hoffmann-La Roche Ag | anticorpos para receptor antitransferrina com afinidade especificada |
TW202330904A (zh) | 2015-08-04 | 2023-08-01 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
RU2753390C1 (ru) | 2015-10-02 | 2021-08-13 | Ф. Хоффманн-Ля Рош Аг | Биспецифические антитела к человеческому cd20/человеческому рецептору трансферрина и способы их применения |
AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
BR112019001138A2 (pt) * | 2016-07-19 | 2019-04-30 | Ibentrus, Inc. | proteínas biespecíficas e métodos para preparar as mesmas |
WO2018039499A1 (en) | 2016-08-24 | 2018-03-01 | Regeneron Pharmaceuticals, Inc. | Host cell protein modification |
US20180206726A1 (en) | 2016-12-07 | 2018-07-26 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
EP3554545A4 (en) * | 2016-12-19 | 2020-08-12 | Vanderbilt University | ANTIBODIES DIRECTED AGAINST HUMAN RESPIRATORY SYNCYTIAL VIRUS PRE-FUSION PROTEIN CONFORMATION AND THEIR USE METHODS |
CN108395482B (zh) | 2017-02-08 | 2021-02-05 | 西比曼生物科技(香港)有限公司 | 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定 |
EP3600416B1 (en) | 2017-03-30 | 2023-06-07 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
CA3067847A1 (en) | 2017-07-06 | 2019-01-10 | Regeneron Pharmaceuticals, Inc. | Cell culture process for making a glycoprotein |
WO2019036855A1 (en) | 2017-08-21 | 2019-02-28 | Adagene Inc. | ANTI-CD137 MOLECULES AND THEIR USE |
CN115925882A (zh) | 2017-12-22 | 2023-04-07 | 瑞泽恩制药公司 | 用于表征药物产品杂质的系统和方法 |
SG11202005235WA (en) | 2018-01-31 | 2020-07-29 | Regeneron Pharma | System and method for characterizing size and charge variant drug product impurities |
TW202311746A (zh) | 2018-02-02 | 2023-03-16 | 美商再生元醫藥公司 | 用於表徵蛋白質二聚合之系統及方法 |
WO2019148445A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
CA3088906A1 (en) | 2018-02-28 | 2019-09-06 | Regeneron Pharmaceuticals, Inc. | Systems and methods for identifying viral contaminants |
EA202092203A1 (ru) | 2018-03-19 | 2020-12-07 | Ридженерон Фармасьютикалз, Инк. | Способы анализа и реагенты для микрочипового капиллярного электрофореза |
TW202016125A (zh) | 2018-05-10 | 2020-05-01 | 美商再生元醫藥公司 | 用於定量及調節蛋白質黏度之系統與方法 |
US20230041197A1 (en) | 2018-06-20 | 2023-02-09 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
US20230009902A1 (en) | 2018-06-20 | 2023-01-12 | Progenity, Inc. | Treatment of a disease or condition in a tissue orginating from the endoderm |
KR20210052389A (ko) | 2018-08-27 | 2021-05-10 | 리제너론 파마슈티칼스 인코포레이티드 | 다운스트림 정제에서의 라만 분광법의 사용 |
WO2020047067A1 (en) | 2018-08-30 | 2020-03-05 | Regeneron Pharmaceuticals, Inc. | Methods for characterizing protein complexes |
AU2019331024A1 (en) | 2018-08-31 | 2021-03-18 | Regeneron Pharmaceuticals, Inc. | Dosing strategy that mitigates cytokine release syndrome for CD3/C20 bispecific antibodies |
EP3852788A1 (en) | 2018-09-17 | 2021-07-28 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Bicistronic chimeric antigen receptors targeting cd19 and cd20 and their uses |
EA202190926A1 (ru) * | 2018-10-01 | 2021-06-25 | Эдисет Био, Инк. | Композиции и способы в отношении сконструированных и несконструированных t-клеток для лечения гематологических опухолей |
WO2020106754A1 (en) | 2018-11-19 | 2020-05-28 | Progenity, Inc. | Methods and devices for treating a disease with biotherapeutics |
EP4220173A3 (en) | 2019-01-16 | 2023-10-18 | Regeneron Pharmaceuticals, Inc. | Methods for characterizing disulfide bonds |
SG11202110911RA (en) | 2019-05-13 | 2021-10-28 | Regeneron Pharma | Improved competitive ligand binding assays |
KR20220066393A (ko) | 2019-09-24 | 2022-05-24 | 리제너론 파아마슈티컬스, 인크. | 크로마토그래피의 사용 및 재생을 위한 시스템 및 방법 |
IL293112A (en) | 2019-11-25 | 2022-07-01 | Regeneron Pharma | Sustained release formulations using non-aqueous emulsions |
WO2021119482A1 (en) | 2019-12-13 | 2021-06-17 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
WO2021150558A1 (en) | 2020-01-21 | 2021-07-29 | Regeneron Pharmaceuticals, Inc. | Deglycosylation methods for electrophoresis of glycosylated proteins |
BR112023003273A2 (pt) | 2020-08-31 | 2023-05-02 | Regeneron Pharma | Estratégias de alimentação de asparagina para melhorar desempenho da cultura celular e mitigar variantes da sequência de asparagina |
KR20230113280A (ko) | 2020-11-25 | 2023-07-28 | 리제너론 파마슈티칼스 인코포레이티드 | 비수성 멤브레인 유화법을 사용한 지속 방출 제형 |
WO2022133135A1 (en) | 2020-12-17 | 2022-06-23 | Regeneron Pharmaceuticals, Inc. | Fabrication of protein-encapsulating microgels |
KR20230134117A (ko) | 2021-01-20 | 2023-09-20 | 리제너론 파마슈티칼스 인코포레이티드 | 세포 배양물에서 단백질 역가를 개선시키는 방법 |
WO2022187323A1 (en) | 2021-03-03 | 2022-09-09 | Regeneron Pharmaceuticals, Inc. | Systems and methods for quantifying and modifying protein viscosity |
WO2022204282A1 (en) | 2021-03-24 | 2022-09-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bicistronic chimeric antigen receptors designed to reduce retroviral recombination and uses thereof |
CA3211302A1 (en) | 2021-03-26 | 2022-09-29 | Ross Kenyon | Methods and systems for developing mixing protocols |
KR20240015646A (ko) | 2021-06-01 | 2024-02-05 | 리제너론 파마슈티칼스 인코포레이티드 | 마이크로칩 모세관 전기영동 분석 및 시약 |
AR127006A1 (es) | 2021-09-08 | 2023-12-06 | Regeneron Pharma | UN MÉTODO BASADO EN ESPECTROMETRÍA DE MASAS Y DE ALTO RENDIMIENTO PARA CUANTIFICAR ANTICUERPOS Y OTRAS PROTEÍNAS QUE CONTIENEN Fc |
KR20240058201A (ko) | 2021-09-20 | 2024-05-03 | 리제너론 파마슈티칼스 인코포레이티드 | 항체 이질성을 제어하는 방법 |
TW202323817A (zh) | 2021-10-07 | 2023-06-16 | 美商再生元醫藥公司 | Ph建模及控制之系統及方法 |
AU2022359898A1 (en) | 2021-10-07 | 2024-03-21 | Regeneron Pharmaceuticals, Inc. | Ph meter calibration and correction |
CA3236367A1 (en) | 2021-10-26 | 2023-05-04 | Michelle Lafond | Systems and methods for generating laboratory water and distributing laboratory water at different temperatures |
TW202346856A (zh) | 2022-03-18 | 2023-12-01 | 美商里珍納龍藥品有限公司 | 分析多肽變體的方法及系統 |
WO2023196903A1 (en) | 2022-04-06 | 2023-10-12 | Regeneron Pharmaceuticals, Inc. | Bispecific antigen-binding molecules that bind and cd3 and tumor associated antigens (taas) and uses thereof |
WO2023215560A1 (en) | 2022-05-05 | 2023-11-09 | Atoosa Corporation | Tumor cell/immune cell multivalent receptor engager – bio-nanoparticle (timre-bnp) |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6893625B1 (en) | 1986-10-27 | 2005-05-17 | Royalty Pharma Finance Trust | Chimeric antibody with specificity to human B cell surface antigen |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
IE922437A1 (en) | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
ATE196606T1 (de) | 1992-11-13 | 2000-10-15 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörpern, die gegen ein differenzierung-antigen gerichtet sind, dessen expression auf menschliche b lymphozyt beschränkt ist, für die behandlung von b-zell-lymphoma |
US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
HU228180B1 (hu) | 1998-08-11 | 2013-01-28 | Biogen Idec Inc | Anti-CD20-ellenanyag alkalmazása B-sejtes limfómák kombinációs terápiájára |
US6224866B1 (en) | 1998-10-07 | 2001-05-01 | Biocrystal Ltd. | Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors |
ES2420835T3 (es) | 1999-04-09 | 2013-08-27 | Kyowa Hakko Kirin Co., Ltd. | Procedimiento para controlar la actividad de las moléculas inmunofuncionales |
AU777970C (en) | 1999-05-07 | 2006-08-17 | F. Hoffman-La Roche Ag | Treatment of autoimmune diseases with antagonists which bind to B cell surface markers |
ITMI991299A1 (it) | 1999-06-11 | 2000-12-11 | Consiglio Nazionale Ricerche | Uso di anticorpi contro antigeni di superficie per il trattamento della malattia trapianto contro ospite |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
CA2476166C (en) | 2002-02-14 | 2011-11-15 | Immunomedics, Inc. | Anti-cd20 antibodies and fusion proteins thereof and methods of use |
US20030233797A1 (en) * | 2002-06-25 | 2003-12-25 | Anderson Dean A. | Air handling system including shroud and grille, and method of use |
ES2744275T3 (es) * | 2002-10-17 | 2020-02-24 | Genmab As | Anticuerpos monoclonales humanos contra CD20 para su uso en el tratamiento de esclerosis múltiple |
US6736137B1 (en) * | 2003-02-28 | 2004-05-18 | Tmr-A, Llc | Protective hooded respirator with oral-nasal cup breathing interface |
US8084582B2 (en) | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
AU2004252067B2 (en) | 2003-05-09 | 2012-04-12 | Duke University | CD20-specific antibodies and methods of employing same |
AR044388A1 (es) | 2003-05-20 | 2005-09-07 | Applied Molecular Evolution | Moleculas de union a cd20 |
DE10334793A1 (de) * | 2003-07-30 | 2005-02-24 | BSH Bosch und Siemens Hausgeräte GmbH | Geschirrspülmaschine |
US20050053602A1 (en) | 2003-08-29 | 2005-03-10 | Genentech, Inc. | Therapy of ocular disorders |
MXPA06006865A (es) | 2003-12-19 | 2006-08-23 | Genentech Inc | Deteccion de cd20 en rechazo de transplante. |
US7850962B2 (en) * | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
US20050271658A1 (en) | 2004-05-05 | 2005-12-08 | Genentech, Inc. | Preventing autoimmune disease |
AU2005251764A1 (en) | 2004-06-04 | 2005-12-22 | Genentech, Inc. | Method for treating lupus |
EP1812060A2 (en) | 2004-10-05 | 2007-08-01 | Genentech, Inc. | Method for treating vasculitis |
TW200714289A (en) | 2005-02-28 | 2007-04-16 | Genentech Inc | Treatment of bone disorders |
CN1331888C (zh) * | 2005-03-02 | 2007-08-15 | 中国人民解放军军事医学科学院生物工程研究所 | 一种抗人b细胞淋巴瘤的单链双特异性抗体 |
AR053579A1 (es) | 2005-04-15 | 2007-05-09 | Genentech Inc | Tratamiento de la enfermedad inflamatoria intestinal (eii) |
MX2007012989A (es) | 2005-04-22 | 2008-01-11 | Genentech Inc | Metodo para tratar la demencia o la enfermedad de alheimer. |
BRPI0611220A2 (pt) * | 2005-06-02 | 2010-08-24 | Astrazeneca Ab | anticorpos direcionados para cd20 e usos dos mesmos |
-
2008
- 2008-07-31 ES ES08796917.6T patent/ES2527297T3/es active Active
- 2008-07-31 ME MEP-2010-15A patent/ME00973B/me unknown
- 2008-07-31 WO PCT/US2008/071709 patent/WO2009018411A1/en active Application Filing
- 2008-07-31 RU RU2010107175/10A patent/RU2486205C2/ru active
- 2008-07-31 PL PL08796917T patent/PL2178916T3/pl unknown
- 2008-07-31 KR KR1020107003899A patent/KR101561020B1/ko active IP Right Grant
- 2008-07-31 MX MX2010000970A patent/MX2010000970A/es active IP Right Grant
- 2008-07-31 BR BRPI0813985-7A patent/BRPI0813985B1/pt active IP Right Grant
- 2008-07-31 US US12/183,274 patent/US7879984B2/en active Active
- 2008-07-31 EP EP08796917.6A patent/EP2178916B1/en active Active
- 2008-07-31 NZ NZ583019A patent/NZ583019A/en unknown
- 2008-07-31 MY MYPI2010000349A patent/MY147651A/en unknown
- 2008-07-31 JP JP2010520180A patent/JP5588865B2/ja not_active Expired - Fee Related
- 2008-07-31 CN CN200880109581.5A patent/CN101809037B/zh active Active
- 2008-07-31 DK DK08796917.6T patent/DK2178916T3/da active
- 2008-07-31 CA CA2695199A patent/CA2695199C/en active Active
- 2008-07-31 AU AU2008282152A patent/AU2008282152B2/en active Active
-
2010
- 2010-01-22 NI NI201000016A patent/NI201000016A/es unknown
- 2010-01-25 ZA ZA2010/00545A patent/ZA201000545B/en unknown
- 2010-01-27 SV SV2010003468A patent/SV2010003468A/es unknown
- 2010-01-27 DO DO2010000037A patent/DOP2010000037A/es unknown
- 2010-01-28 CR CR11243A patent/CR11243A/es unknown
- 2010-01-29 GT GT201000026A patent/GT201000026A/es unknown
- 2010-01-29 HN HN2010000202A patent/HN2010000202A/es unknown
- 2010-01-29 TN TNP2010000054A patent/TN2010000054A1/fr unknown
- 2010-02-01 TN TNP2010000056A patent/TN2010000056A1/fr unknown
- 2010-02-24 MA MA32651A patent/MA31634B1/fr unknown
- 2010-02-26 EC EC2010010005A patent/ECSP10010005A/es unknown
- 2010-02-26 CO CO10023468A patent/CO6260105A2/es active IP Right Grant
- 2010-08-30 HK HK10108217.8A patent/HK1141811A1/xx unknown
- 2010-12-13 US US12/965,956 patent/US8097713B2/en active Active
-
2011
- 2011-12-13 US US13/323,875 patent/US8329181B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2178916T3 (da) | Humane antistoffer mod human cd20 og fremgangsmåde til anvendelse deraf | |
DK3064511T3 (da) | Medicinsk anvendelse af humane højaffinitetsantistoffer til human il-4-receptor | |
KR101577843B1 (ko) | 인간 ox40 수용체에 대한 결합 분자 | |
KR101896129B1 (ko) | 인간 tnf-유사 리간드 1a(tl1a)에 대한 인간 항체 | |
KR101709495B1 (ko) | 인간 신경성장인자에 대한 고친화성 인간 항체 | |
KR20190030206A (ko) | 항-지카 바이러스 항체 및 사용 방법 | |
KR20150046789A (ko) | 항-cd3 항체, cd3 및 cd20에 결합하는 이특이적 항원-결합 분자, 및 이들의 사용 | |
JP2011072317A (ja) | アンタゴニスト抗cd40モノクローナル抗体およびそれらを使用するための方法 | |
AU2014216019B2 (en) | High affinity human antibodies to Human IL-4 receptor |